Oncology is a $200B+ global category moving through its most consequential therapeutic reset since the original chemotherapy era. The immuno-oncology, antibody-drug conjugate, CAR-T, and cell-and-gene-therapy frontier is repricing the entire portfolio between earnings calls. Reimbursement decisions, AdComm calendar items, and label expansions in flight through 2025–2026 will determine the next decade of oncology run-rate. AimwellBio is the only indication pipeline that layers NCI SEER population epidemiology — incidence, survival, mortality, and prevalence — directly on top of corporate, regulatory, and clinical signals. No other coverage carries this dimension.
Adversarial verification is the cost of being early.
Checkpoint inhibitors, antibody-drug conjugates, CAR-T, and bispecifics are reshaping the $200B+ oncology run-rate simultaneously. Reimbursement decisions and label expansions in flight through 2025–2026 will determine which manufacturers capture the next cycle of oncology spend. AimwellBio tracks every payer revision, AdComm calendar item, and indication-expansion filing against the companies under your coverage.
AimwellBio integrates NCI SEER Cancer Stat Facts directly into the oncology signal pool: incidence trends, 5-year relative survival, mortality, and lifetime risk across 30 cancer sites. No other indication pipeline carries this dimension. It is the proof that AimwellBio's intelligence layer extends from corporate filings to population outcomes — the ground truth against which every reimbursement, label, and procurement decision will ultimately be measured.
Every oncology signal carries provenance, source method, and confidence. SEER is public NCI data. ClinicalTrials.gov is public NIH data. SEC filings are public regulator data. AimwellBio verifies, it does not generate. There is no hallucination tolerance for ministry-grade procurement, an investment-committee memo, or a medical-affairs brief delivered to a global oncology KOL.
Oncology is repricing inside a regulatory, reimbursement, and sovereign-procurement window most portfolio teams will read about after it closes. The numbers below are the consequences of operating without an adversarial verification layer — and without a population epidemiology floor under it.
global oncology run-rate. Single-indication coverage misses cross-tumor signal cascades — the ADC platform read-across, the checkpoint combo failure, the CAR-T solid-tumor breakthrough.
relative survival for the bottom-quintile cancers — pancreatic, esophageal, liver, lung — remains below 25%. Investors not tracking SEER survival deltas miss the reimbursement trigger when a label moves the curve.
typical lag between an FDA AdComm vote and equity repricing. AdComm dispatch is non-optional for oncology funds. Yesterday’s thesis is not a position.
second chances on a Vision 2030 oncology procurement decision. King Faisal Specialist Hospital and Cleveland Clinic Abu Dhabi anchor the GCC sovereign care layer. The window does not reopen.
Each entity is mapped into AIMN:ATLAS with continuous SEC, ClinicalTrials.gov, PubMed, and NCI SEER coverage. Sovereign-tagged anchors across KSA and the GCC are flagged. Click any name to open its company dossier.
The Surveillance, Epidemiology, and End Results program is the National Cancer Institute’s population-level cancer registry — the ground-truth dataset that defines what is actually happening in incidence, 5-year relative survival, mortality, and lifetime risk across the United States. AimwellBio integrates 30 SEER cancer-site stat facts directly into the oncology signal pool, alongside ClinicalTrials.gov, SEC, and PubMed. The result: every clinical readout, label expansion, and reimbursement decision is read against the population curve it claims to bend.
Free public cancer data, decision-grade intelligence. Premium linked datasets — SEER-Medicare, SEER-CAHPS, and the SEER residual-survival linkage — are reserved for the question that deserves them. The architecture is the same one that supports a sovereign procurement decision: every signal traceable, every recommendation cited, every assumption falsifiable.
Discuss SEER-integrated oncology coverage →Every public and pre-IPO oncology name carries reimbursement, AdComm, and clinical-readout risk. AimwellBio delivers cited diligence — with SEER population context underneath — before the conviction memo, not after it.
The oncology landscape moves between earnings calls. AimwellBio tracks pipeline, IP, and indication-expansion signals across the full coverage universe — ADC, CAR-T, bispecific, and cell-and-gene-therapy.
Real-world evidence and KOL movement on minimal residual disease, circulating tumor DNA, and immune-checkpoint long-term outcomes arrive faster than any single team can read. AimwellBio structures the frontier into briefable units.